Daniel Ajona1, María J Pajares, Leticia Corrales, Jose L Perez-Gracia, Jackeline Agorreta, Maria D Lozano, Wenceslao Torre, Pierre P Massion, Juan P de-Torres, Eloisa Jantus-Lewintre, Carlos Camps, Javier J Zulueta, Luis M Montuenga, Ruben Pio. 1. Affiliations of authors: Division of Oncology, Center for Applied Medical Research, Pamplona, Spain (DA, MJP, LC, JA, LMM, RP); Department of Histology and Pathology (MJP, JA, LMM) and Department of Biochemistry and Genetics (RP) School of Medicine, University of Navarra, Pamplona, Spain; Department of Oncology (JLP), Department of Pathology (MDL), Department of Thoracic Surgery (WT), Department of Pulmonary Medicine (JPdT, JJZ) Clínica Universidad de Navarra, Pamplona, Spain; Thoracic Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN (PPM); Department of Medicine, University of Valencia, Valencia, Spain (CC); Department of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain (CC); Molecular Oncology Laboratory, Fundación para la Investigación del Hospital General Universitario de Valencia, Valencia, Spain (EJL).
Abstract
BACKGROUND: There is a medical need for diagnostic biomarkers in lung cancer. We evaluated the diagnostic performance of complement activation fragments. METHODS: We assessed complement activation in four bronchial epithelial and seven lung cancer cell lines. C4d, a degradation product of complement activation, was determined in 90 primary lung tumors; bronchoalveolar lavage supernatants from patients with lung cancer (n = 50) and nonmalignant respiratory diseases (n = 22); and plasma samples from advanced (n = 50) and early lung cancer patients (n = 84) subjects with inflammatory lung diseases (n = 133), and asymptomatic individuals enrolled in a lung cancer computed tomography screening program (n = 190). Two-sided P values were calculated by Mann-Whitney U test. RESULTS: Lung cancer cells activated the classical complement pathway mediated by C1q binding that was inhibited by phosphomonoesters. Survival was decreased in patients with high C4d deposition in tumors (hazard ratio [HR] = 3.06; 95% confidence interval [CI] = 1.18 to 7.91). C4d levels were increased in bronchoalveolar lavage fluid from lung cancer patients compared with patients with nonmalignant respiratory diseases (0.61 ± 0.87 vs 0.16 ± 0.11 µg/mL; P < .001). C4d levels in plasma samples from lung cancer patients at both advanced and early stages were also increased compared with control subjects (4.13 ± 2.02 vs 1.86 ± 0.95 µg/mL, P < 0.001; 3.18 ± 3.20 vs 1.13 ± 0.69 µg/mL, P < .001, respectively). C4d plasma levels were associated with shorter survival in patients at advanced (HR = 1.59; 95% CI = 0.97 to 2.60) and early stages (HR = 5.57; 95% CI = 1.60 to 19.39). Plasma C4d levels were reduced after surgical removal of lung tumors (P < .001) and were associated with increased lung cancer risk in asymptomatic individuals with (n = 32) or without lung cancer (n = 158) (odds ratio = 4.38; 95% CI = 1.61 to 11.93). CONCLUSIONS: Complement fragment C4d may serve as a biomarker for early diagnosis and prognosis of lung cancer.
BACKGROUND: There is a medical need for diagnostic biomarkers in lung cancer. We evaluated the diagnostic performance of complement activation fragments. METHODS: We assessed complement activation in four bronchial epithelial and seven lung cancer cell lines. C4d, a degradation product of complement activation, was determined in 90 primary lung tumors; bronchoalveolar lavage supernatants from patients with lung cancer (n = 50) and nonmalignant respiratory diseases (n = 22); and plasma samples from advanced (n = 50) and early lung cancerpatients (n = 84) subjects with inflammatory lung diseases (n = 133), and asymptomatic individuals enrolled in a lung cancer computed tomography screening program (n = 190). Two-sided P values were calculated by Mann-Whitney U test. RESULTS:Lung cancer cells activated the classical complement pathway mediated by C1q binding that was inhibited by phosphomonoesters. Survival was decreased in patients with high C4d deposition in tumors (hazard ratio [HR] = 3.06; 95% confidence interval [CI] = 1.18 to 7.91). C4d levels were increased in bronchoalveolar lavage fluid from lung cancerpatients compared with patients with nonmalignant respiratory diseases (0.61 ± 0.87 vs 0.16 ± 0.11 µg/mL; P < .001). C4d levels in plasma samples from lung cancerpatients at both advanced and early stages were also increased compared with control subjects (4.13 ± 2.02 vs 1.86 ± 0.95 µg/mL, P < 0.001; 3.18 ± 3.20 vs 1.13 ± 0.69 µg/mL, P < .001, respectively). C4d plasma levels were associated with shorter survival in patients at advanced (HR = 1.59; 95% CI = 0.97 to 2.60) and early stages (HR = 5.57; 95% CI = 1.60 to 19.39). Plasma C4d levels were reduced after surgical removal of lung tumors (P < .001) and were associated with increased lung cancer risk in asymptomatic individuals with (n = 32) or without lung cancer (n = 158) (odds ratio = 4.38; 95% CI = 1.61 to 11.93). CONCLUSIONS: Complement fragment C4d may serve as a biomarker for early diagnosis and prognosis of lung cancer.
Authors: Josep Villanueva; David R Shaffer; John Philip; Carlos A Chaparro; Hediye Erdjument-Bromage; Adam B Olshen; Martin Fleisher; Hans Lilja; Edi Brogi; Jeff Boyd; Marta Sanchez-Carbayo; Eric C Holland; Carlos Cordon-Cardo; Howard I Scher; Paul Tempst Journal: J Clin Invest Date: 2006-01 Impact factor: 14.808
Authors: Rohit Ghai; Patrick Waters; Lubka T Roumenina; Mihaela Gadjeva; Mihaela S Kojouharova; Kenneth B M Reid; Robert B Sim; Uday Kishore Journal: Immunobiology Date: 2006-12-12 Impact factor: 3.144
Authors: Mitsuo Sato; Melville B Vaughan; Luc Girard; Michael Peyton; Woochang Lee; David S Shames; Ruben D Ramirez; Noriaki Sunaga; Adi F Gazdar; Jerry W Shay; John D Minna Journal: Cancer Res Date: 2006-02-15 Impact factor: 12.701
Authors: Marcin Okroj; Leticia Corrales; Anna Stokowska; Ruben Pio; Anna M Blom Journal: Cancer Immunol Immunother Date: 2009-03-04 Impact factor: 6.968
Authors: Maciej M Markiewski; Robert A DeAngelis; Fabian Benencia; Salome K Ricklin-Lichtsteiner; Anna Koutoulaki; Craig Gerard; George Coukos; John D Lambris Journal: Nat Immunol Date: 2008-09-28 Impact factor: 25.606
Authors: Tzu-Fang Lou; Deepa Sethuraman; Patrick Dospoy; Pallevi Srivastva; Hyun Seok Kim; Joongsoo Kim; Xiaotu Ma; Pei-Hsuan Chen; Kenneth E Huffman; Robin E Frink; Jill E Larsen; Cheryl Lewis; Sang-Won Um; Duk-Hwan Kim; Jung-Mo Ahn; Ralph J DeBerardinis; Michael A White; John D Minna; Hyuntae Yoo Journal: Cancer Prev Res (Phila) Date: 2015-10-28
Authors: George Hajishengallis; Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; John D Lambris Journal: Nat Immunol Date: 2017-11-16 Impact factor: 25.606
Authors: Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris Journal: Nat Rev Immunol Date: 2017-09-18 Impact factor: 53.106
Authors: Daniel Ajona; Carolina Zandueta; Leticia Corrales; Haritz Moreno; María J Pajares; Sergio Ortiz-Espinosa; Elena Martínez-Terroba; Naiara Perurena; Fernando J de Miguel; Eloisa Jantus-Lewintre; Carlos Camps; Silvestre Vicent; Jackeline Agorreta; Luis M Montuenga; Ruben Pio; Fernando Lecanda Journal: Am J Respir Crit Care Med Date: 2018-05-01 Impact factor: 21.405
Authors: Britney Reese; Ashok Silwal; Elizabeth Daugherity; Michael Daugherity; Mahshid Arabi; Pierce Daly; Yvonne Paterson; Layton Woolford; Alana Christie; Roy Elias; James Brugarolas; Tao Wang; Magdalena Karbowniczek; Maciej M Markiewski Journal: J Immunol Date: 2020-11-06 Impact factor: 5.422
Authors: Lubka T Roumenina; Marie V Daugan; Florent Petitprez; Catherine Sautès-Fridman; Wolf Herman Fridman Journal: Nat Rev Cancer Date: 2019-10-30 Impact factor: 60.716